Lactobacillus casei: The Workhorse Probiotic With 80 Years of Research

Lactobacillus casei is one of the oldest and most-studied names in the probiotic world — the strain on the front of Yakult bottles in 80 countries, the live culture in DanActive yogurt drinks, and the workhorse organism in research papers going back to the 1930s. It also sits in the middle of one of the most confusing reclassifications in modern microbial taxonomy. Here’s what the research actually says.

The short answer

Lactobacillus casei is a Gram-positive, lactic-acid-producing probiotic species in the Lacticaseibacillus group (alongside L. paracasei and L. rhamnosus). It has a roughly 80-year track record in clinical and food research, anchored by three commercial strains: Shirota (the strain in Yakult, in continuous use since 1935), DN-114001 (the strain in DanActive yogurt drinks), and casei 01. Published research has explored these strains for cold-season immune resilience, traveler’s diarrhea, immune-marker shifts in healthy adults, and adjunct supportive roles in cancer-immunotherapy settings. As with every probiotic, the specific strain matters more than the species name — a label that says only “L. casei” with no strain code is telling you very little.

What L. casei is (and the 2020 reclassification)

Lactobacillus casei is a Gram-positive, rod-shaped, facultatively anaerobic bacterium that ferments lactose and other sugars into lactic acid — the metabolic signature of the broader lactic-acid bacteria family. The species was first formally described in the late 19th century and isolated from cheese (the name casei literally means “of cheese” in Latin). It has been a subject of microbial research continuously since the 1930s, making it one of the longest-studied organisms in the probiotic field.

In 2020, the genus Lactobacillus underwent a major taxonomic revision (Zheng et al., 2020). What had been a single, sprawling genus containing more than 260 species was split into 25 genera based on genome-sequence data. The “casei group” — L. casei, L. paracasei, and L. rhamnosus — were moved together into a new genus called Lacticaseibacillus. So the formally correct modern name is Lacticaseibacillus casei.

In practice, both the older Lactobacillus casei naming and the newer Lacticaseibacillus casei naming are used interchangeably on supplement labels, in research papers published during the transition years, and in regulatory documents. This guide uses the historical Lactobacillus form because that is what nearly every consumer product still displays. If you see Lacticaseibacillus casei on a label, it is the same organism. For broader context on how the major Lactobacillus species divide labor in the digestive tract, see our gut health glossary.

Where it’s naturally found

L. casei bridges three worlds — the human gut, the fermented-food kitchen, and the oral cavity. You’ll encounter it in:

• Yakult fermented milk drinks — the small bottle marketed in roughly 40 countries delivers approximately 6.5–20 billion CFU of L. casei Shirota per serving, depending on the regional formulation. Yakult has been in continuous commercial production since 1935 in Japan, making the Shirota strain one of the longest commercially-tracked probiotics in human history.
• DanActive yogurt drinks — the Danone product line (sold as Actimel in Europe and DanActive in North America) features L. casei DN-114001 alongside the standard yogurt-starter cultures. Several large clinical trials have been conducted on this specific delivery format.
• Aged cheeses — Cheddar, Parmesan, Manchego, and other long-ripened cheeses develop L. casei as part of their natural maturation flora. It contributes to flavor development, particularly the savory and slightly tangy notes that emerge over months of aging.
• The human gastrointestinal tract and oral cavity — L. casei is a normal resident microbe in many healthy adults, found in the small intestine, colon, and mouth. It is part of the baseline microbial ecology in people who consume fermented dairy regularly.
• Some fermented plant foods — certain pickled vegetables, sourdough cultures, and traditional fermented preparations also harbor L. casei as part of the wild fermentation community, although in smaller quantities than dairy sources.

The dual food-and-gut origin is part of why L. casei has one of the longest safety records in the probiotic category — humans have been consuming it in cultured dairy for thousands of years.

The named strains: Shirota, DN-114001, casei 01

This is the most important section if you’re evaluating a product. Probiotic research is strain-specific. A clinical outcome documented for L. casei Shirota does not automatically transfer to a generic “L. casei” entry on a different product. Here are the strains with substantial published human research:

• L. casei Shirota (also known as LcS or YIT 9029) — the Yakult flagship strain, isolated by Dr. Minoru Shirota in Kyoto in 1930 and in continuous commercial use since 1935. The most-studied probiotic strain in Japan and the subject of more than 100 published human trials. Research has explored Shirota for cold-season immune resilience, bowel-habit support, immune-marker shifts in adults under stress, and supportive roles in oncology settings (Routy 2017).
• L. casei DN-114001 (also known as CNCM I-1518) — the Danone strain in DanActive / Actimel. Studied in multiple large randomized trials, most notably Merenstein and colleagues (2010) for upper-respiratory and gastrointestinal symptom days in school-age children, and Guillemard and colleagues for cold-season outcomes in older adults.
• L. casei 01 (also known as Lc-01 or LAFTI L26) — an Australian-origin strain used in some capsule-format probiotic supplements and in functional dairy in Australia and Asia. Smaller research base than Shirota or DN-114001 but appears in some multi-strain blends.
• L. casei Zhang — a Chinese-origin strain isolated from traditional fermented dairy in Inner Mongolia, studied for general gut-microbiome balance and cholesterol-marker outcomes in regional research.
• Other strains — ATCC 393 (the type strain, used heavily in academic research), CRL 431 (Chr. Hansen), and several proprietary commercial strains round out the field.

In a quality multi-strain formula, the Supplement Facts panel should disclose either the strain designation or, at minimum, the source strain library. Products that print “L. casei” with no further information are using the species name as marketing language rather than as a specific clinical claim. For broader strain context across the genus, see our L. paracasei guide — the immune-adjacent sister species.

What 80 years of research has explored

L. casei has one of the deepest research benches of any probiotic species, going back to the 1930s. The summary below describes published findings — not claims that the strain treats, prevents, or cures any condition.

• Immune support: large-scale meta-analysis. Sazawal and colleagues (2014) and related meta-analyses have summarized multiple randomized trials of L. casei strains (primarily Shirota and DN-114001) in healthy adult and pediatric populations. Pooled findings reported favorable trends in upper-respiratory and gastrointestinal symptom days versus placebo. The strain-specific evidence is strongest for Shirota and DN-114001.
• Cold-season resilience in healthy adults. Maruyama and colleagues (2016) and earlier work by Guillemard and colleagues explored L. casei in adults during cold-season months, measuring upper-respiratory symptom days, common-cold incidence, and immune markers (natural killer cell activity, cytokine profiles). Reported findings included favorable trends in aggregate symptom days and immune-marker shifts versus placebo. This is exploratory research on immune adjacency — not a claim that the strain treats or prevents colds.
• Supportive role in cancer immunotherapy settings. Routy and colleagues (2017), published in Science, reported that gut microbiome composition — including the presence of specific Lactobacillus and Bifidobacterium species — was associated with response to checkpoint-inhibitor immunotherapy in cancer patients. Subsequent translational research has explored whether specific probiotic strains (including L. casei Shirota) might play a supportive role alongside oncology treatment, always under physician supervision. This is research-stage work, not a clinical recommendation.
• Traveler’s diarrhea. Manley and colleagues (2007), among other studies, examined L. casei strains in travelers to high-risk destinations, measuring incidence and duration of diarrhea episodes versus placebo. Findings have been mixed across the literature, with some strains and dosing regimens showing favorable trends and others showing no significant difference. The strongest probiotic evidence in this category sits with S. boulardii, but L. casei appears in some travel-protocol research.
• General gut-microbiome balance. The ISAPP consensus statement (Hill et al., 2014) emphasizes that probiotic effects are strain-specific and dose-specific. L. casei, when administered as part of a multi-strain blend, contributes to the overall ecological signature of the supplemented gut — lactic-acid production, competitive exclusion of less-desirable microbes, and short-chain fatty acid pathway support.

A consistent thread across this research: outcomes are strain-specific and dose-specific. Benefits documented for one strain at a specific dose do not transfer to other strains or other doses.

Typical research dosing

Clinical trials of L. casei have used a wide dosing range, generally between 1 billion and 100 billion CFU per day, depending on the strain, the format, and the outcome being measured. Specific examples from the published literature:

• Yakult Shirota trials have typically used 6.5–20 billion CFU per day, delivered as one or two small fermented-milk bottles, over 4–12 weeks for immune-marker outcomes.
• DanActive DN-114001 trials in school-age children commonly used 1–2 bottles per day (each providing approximately 10 billion CFU), over 90–180 days for symptom-day outcomes.
• Capsule-format research with L. casei 01 and similar strains has used 1–10 billion CFU per day in multi-strain blends.
• Higher-dose oncology-adjacent research has explored doses up to 100 billion CFU per day, always under clinical supervision.

In a multi-strain capsule, L. casei is one component of a larger blend. The total CFU on the product label represents the combined dose across all strains. A formula listing 50 billion CFU across seven strains is not delivering 50 billion of casei alone — the per-strain dose is a fraction of the total, which is appropriate for daily supportive use rather than therapeutic dosing.

Safety profile

L. casei has one of the longest implicit safety records in the probiotic category because humans have consumed it in fermented dairy for thousands of years and in Yakult specifically since 1935. Specific strains carry “Qualified Presumption of Safety” status with the European Food Safety Authority and “Generally Recognized as Safe” status under FDA framework when used as a food ingredient.

In daily-use clinical trials, reported adverse events are uncommon and typically limited to short-lived mild digestive shifts (gas, bloating, stool-pattern changes) during the first week of supplementation as the gut adjusts. These effects generally resolve without intervention. The dairy-delivery formats (Yakult, DanActive) are well-tolerated by most lactose-sensitive individuals because the live-culture fermentation reduces residual lactose, though people with severe dairy allergy or galactose-related metabolic conditions should avoid dairy-delivered probiotics and choose capsule formats instead.

As with all live probiotics, individuals with severely compromised immune systems, central venous catheters, recent abdominal surgery, or critical illness should consult a clinician before starting a probiotic supplement. This caution applies to the entire probiotic category, not specifically to L. casei.

L. casei vs. L. paracasei vs. L. rhamnosus

These three species are taxonomic siblings — together they form the Lacticaseibacillus genus, and for most of the 20th century they were lumped together as the “L. casei group” in older microbiology literature. Modern gene-sequencing distinguishes them as separate species, formally reclassified in 2020. Shoppers often want to know which to choose. The honest answer is they do meaningfully different jobs in a comprehensive formula, and the strongest products include more than one.

• L. casei — the workhorse with 80+ years of commercial and clinical history. Strongest research for cold-season immune resilience and immune-marker shifts in healthy adults, anchored by the Shirota and DN-114001 strains. Best understood as a daily immune-adjacent probiotic with deep food-history safety.
• L. paracasei — the immune-adjacent and oral-health adjunct. Strongest research for nasal-passage comfort during pollen season, atopic skin-barrier support, and oral cavity ecology. Best understood as a specialty probiotic that complements a foundational gut blend.
• L. rhamnosus — the bile-tolerant survivor strain. Strongest research for daily digestive support, post-antibiotic recovery, and gut adherence. The GG strain has hundreds of clinical trials behind it. Best understood as the foundational gut probiotic of the three.

Because older labels and older research papers sometimes used the names interchangeably, a strain originally described as L. casei may have been reclassified as L. paracasei after gene-sequencing. The practical takeaway: treat the three as cousins with overlapping — but not identical — clinical research bases. For full context, see our L. paracasei and L. rhamnosus guides.

Who might benefit most from L. casei

Based on the research base summarized above, the people most likely to find L. casei a useful addition to a daily probiotic routine include:

• Adults seeking immune support during cold-season months — particularly those drawn to the Shirota or DN-114001 strain research base.
• People who already enjoy fermented dairy as part of their diet and want a consistent, documented-strain delivery format alongside or instead of yogurt drinks.
• Adults who travel frequently to high-risk destinations and want a documented strain as part of a broader pre-trip preparation routine, alongside food and water precautions.
• Older adults looking to support immune-marker resilience as part of a daily routine — the strain has been studied specifically in older-adult cohorts.
• Anyone building a comprehensive multi-strain probiotic routine who wants species diversity beyond the standard acidophilus-rhamnosus-bifido core.

L. casei is not the right primary choice for someone whose first concern is occasional constipation, post-antibiotic recovery, or upper-GI mucosal support — those goals are better-served by strains and ingredients with stronger evidence in those territories. It earns its place in the formula as a deeply-researched immune-adjacent contributor with one of the longest food-history safety records in the category.

The bottom line

Lactobacillus casei is the elder statesman of the probiotic category. The Shirota strain has been in continuous commercial use since 1935, the DanActive strain has multiple large randomized trials behind it, and the species as a whole has roughly 80 years of cumulative research history. The 2020 reclassification into Lacticaseibacillus casei is a taxonomic refinement, not a redefinition — it’s the same organism with a more accurate genus name.

The honest framing matters. L. casei is a dietary ingredient that supports the body’s normal structure and function. Research has explored its role in immune adjacency, cold-season resilience, and supportive contexts in oncology and travel settings, but it is not a treatment for any disease. As a deeply-researched component inside a well-designed multi-strain blend — or as a single-strain daily delivery through Yakult or DanActive — it earns its long-running place in the probiotic conversation through one of the densest evidence bases and one of the longest safety records in the category.